Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dynogen: Let the bladder beware

As anyone who has cared for an elderly parent knows, an aging population means an increasing number of patients will suffer from disorders such as urinary incontinence. The few existing drugs include ditropan, which has been on the market for about 40 years, and Detrol tolteridine. But both are anticholinergics, which can have side effects such as dry mouth, constipation, the inability to sweat and an increase in residual urine.

Dynogen

Read the full 712 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE